奥曲肽联合奥美拉唑对胃癌恶性肠梗阻患者临床症状及血清炎症因子水平的影响  

Influence of octreotide combined with omeprazole on clinical symptoms and serum inflammatory factors levels in patients with gastric cancer and malignant bowel obstruction

作　　者：刘辉 刘明 金璿[3] LIU Hui;LIU Ming;JIN Xuan(Department of Oncology,Huguosi Hospital of Traditional Chinese Medicine Affiliated to Beijing University of Traditional Chinese Medicine,Beijing 100035,China;Department of General Surgery,Beijing Xicheng District Zhanlan Road Hospital,Beijing 100044,China;Department of Oncology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京中医药大学附属护国寺中医医院肿瘤科,北京100035 [2]北京市西城区展览路医院普外科,北京100044 [3]北京大学第一医院肿瘤科,北京100034

出　　处：《癌症进展》2025年第8期932-935,共4页Oncology Progress

摘　　要：目的目的探讨奥曲肽联合奥美拉唑对胃癌恶性肠梗阻患者临床症状及血清炎症因子水平的影响。方法根据治疗方法的不同将86例胃癌恶性肠梗阻患者分为研究组(n=43,奥曲肽联合奥美拉唑治疗)和对照组(n=43,奥曲肽治疗)。比较两组患者的临床疗效、胃肠减压量、生活质量[卡氏功能状态(KPS)评分]、恢复指标、血清炎症因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]水平及不良反应发生情况。结果结果治疗7天后,研究组患者总有效率高于对照组,差异有统计学意义(P﹤0.05)。治疗7天后,两组患者胃肠减压量及IL-6、CRP、TNF-α水平均降低,KPS评分均升高,研究组患者胃肠减压量及IL-6、CRP、TNF-α水平均低于对照组,KPS评分高于对照组,差异均有统计学意义(P﹤0.05)。研究组患者首次排气时间、首次排便时间、腹痛消失时间、呕吐停止时间均明显短于对照组,差异均有统计学意义(P﹤0.01)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论结论奥曲肽联合奥美拉唑可提高胃癌恶性肠梗阻患者的治疗有效率和生活质量,降低胃肠减压量和炎症因子水平,缓解临床症状,且具有一定的安全性。Objective To explore the influence of octreotide combined with omeprazole on clinical symptoms and se-rum inflammatory factors levels in patients with gastric cancer and malignant bowel obstruction.Method According to different treatment methods,86 patients with gastric cancer and malignant bowel obstruction were divided into study group(n=43,octreotide combined with omeprazole treatment)and control group(n=43,octreotide treatment).The clini-cal efficacy,gastrointestinal decompression amount,quality of life[Karnofsky performance status(KPS)score],recovery indexes,serum inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)]levels and adverse reactions were compared between the two groups.Result After 7 days of treatment,the total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After 7 days of treatment,the gastrointestinal decompression amount and levels of IL-6,CRP and TNF-αwere decreased in both groups,while KPS scores were increased in both groups,the gastrointestinal decompression amount and levels of IL-6,CRP and TNF-αin study group were lower than those in control group,and KPS score was higher than that in con-trol group,the differences were statistically significant(P<0.05).The first exhaust time,the first defecation time,the dis-appearance time of abdominal pain and the cessation time of vomiting in the study group were significantly shorter than those in the control group,and the differences were statistically significant(P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Octreotide combined with omeprazole can improve the treatment efficiency and quality of life in patients with gastric cancer and malignant intesti-nal obstruction,reduce the amount of gastrointestinal decompression and the level of inflammatory factors,relieve clini-cal symptoms,and has certain safety.

关 键 词：奥曲肽 奥美拉唑 胃癌 恶性肠梗阻 临床症状 炎症因子 

分 类 号：R735.2[医药卫生—肿瘤]